Every Research Peptide Explained: The Complete 2026 Comparison Guide

Why Researchers Are Comparing Peptides in 2026

The research peptide landscape has expanded dramatically over the past several years. What was once a niche field dominated by a handful of growth hormone secretagogues has grown into a sprawling ecosystem of compounds spanning weight loss, tissue repair, cognitive enhancement, longevity, mitochondrial function, sexual health, and metabolic optimization. For researchers entering this space — or experienced investigators expanding their scope — understanding what each peptide does, how it works, and where it fits relative to other compounds is essential.

This guide covers every major research peptide currently available for in-vitro and laboratory investigation. Each section explains the compound’s mechanism of action, what the published research literature reports, how it compares to related peptides, and what researchers should know before incorporating it into their protocols. Whether you are searching for a peptide comparison chart, trying to understand the differences between research peptides, or looking for a comprehensive peptide guide for researchers, this article is designed to be the most thorough single resource available.

Weight Loss and Metabolic Peptides

The metabolic peptide category has seen the most public attention thanks to the success of GLP-1 receptor agonists in clinical settings. Research-grade compounds in this space target appetite regulation, glucose metabolism, fat oxidation, and energy expenditure through various receptor pathways.

Retatrutide (GLP-1/GIP/Glucagon Triple Agonist)

Retatrutide is a triple agonist peptide that simultaneously activates three receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). This triple mechanism places it at the forefront of multi-receptor metabolic research. In published clinical trial data, retatrutide produced up to 24% body weight reduction over 48 weeks in phase 2 trials — the highest figure reported for any obesity compound in controlled human studies at the time of publication.

The GLP-1R component drives appetite suppression and improved glycemic control. The GIPR component enhances the metabolic effects of GLP-1R activation and may independently improve lipid handling. The glucagon receptor component is what distinguishes retatrutide from dual agonists — glucagon activation increases hepatic fat oxidation, raises energy expenditure, and contributes to the compound’s exceptional weight loss efficacy. Researchers investigating retatrutide vs tirzepatide note that the addition of glucagon receptor agonism appears to account for the incremental efficacy gain over dual GLP-1/GIP compounds.

Key search terms researchers use: retatrutide weight loss results, triple agonist peptide research, GLP-1 GIP glucagon agonist, reta peptide benefits

Tirzepatide (GLP-1/GIP Dual Agonist)

Tirzepatide is a dual agonist peptide targeting GLP-1R and GIPR. It was the first dual incretin agonist to receive clinical approval (as Mounjaro for diabetes and Zepbound for obesity). In phase 3 clinical trials, tirzepatide produced up to 22.5% body weight reduction — a landmark result that helped establish multi-receptor agonism as a superior approach to single-target GLP-1R agonism for metabolic research.

The dual mechanism is believed to produce synergistic effects: GLP-1R activation provides appetite suppression and glucose-dependent insulin secretion, while GIPR activation enhances these effects and may independently improve adipose tissue metabolism and reduce inflammation. Researchers comparing tirzepatide vs semaglutide consistently note that the dual mechanism produces greater weight loss and metabolic improvement than GLP-1R agonism alone.

For researchers interested in the incretin pathway, tirzepatide research-grade compound provides an opportunity to study dual receptor activation in controlled laboratory settings, examining how the addition of GIPR agonism modifies the metabolic response profile compared to selective GLP-1R agonists.

Key search terms: tirzepatide research peptide, dual agonist GLP-1 GIP, tirzepatide mechanism of action, tirzepatide vs retatrutide comparison

Tesamorelin (Growth Hormone Releasing Hormone Analogue)

Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. Unlike direct GH administration, tesamorelin preserves the body’s natural pulsatile release pattern and feedback mechanisms. It was originally developed and studied in the context of HIV-associated lipodystrophy, where it demonstrated significant reductions in visceral adipose tissue.

In research settings, tesamorelin is studied for its effects on body composition, particularly the reduction of visceral fat — the metabolically active fat surrounding internal organs that is associated with insulin resistance, cardiovascular risk, and systemic inflammation. Published research has shown that tesamorelin for visceral fat reduction produces measurable decreases in trunk fat without the supraphysiological GH levels that come with direct GH injection. Researchers also investigate tesamorelin’s potential effects on cognitive function, as growth hormone and IGF-1 signaling play roles in neuroplasticity and memory.

Key search terms: tesamorelin peptide benefits, tesamorelin vs HGH, GHRH analogue research, tesamorelin visceral fat reduction, tesamorelin cognitive effects

MOTS-c (Mitochondrial-Derived Peptide)

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — making it one of the few known mitochondrial-derived peptides (MDPs) with significant metabolic signaling functions. It activates AMPK (AMP-activated protein kinase), the master cellular energy sensor, and has been described in published research as an “exercise mimetic” due to its ability to activate some of the same metabolic pathways triggered by physical activity.

Research on MOTS-c spans metabolic regulation, insulin sensitivity, exercise physiology, and aging. Published studies have demonstrated that MOTS-c peptide benefits include improved glucose uptake in skeletal muscle, enhanced fatty acid oxidation, reduced insulin resistance in diet-induced obesity models, and improved exercise capacity. MOTS-c levels naturally decline with age, which has led researchers to investigate it as a potential factor in age-related metabolic decline.

What makes MOTS-c unique among metabolic peptides is its mitochondrial origin and its mechanism of action through AMPK rather than through hormone receptors. This gives it a fundamentally different pathway from incretin-based compounds like retatrutide or tirzepatide, making it a complementary rather than competing area of research.

Key search terms: MOTS-c research peptide, mitochondrial peptide benefits, MOTS-c exercise mimetic, MOTS-c AMPK activation, MOTS-c vs exercise

SLU-PP-332 (ERRα/γ Agonist — Oral Exercise Mimetic)

SLU-PP-332 is a small-molecule agonist of estrogen-related receptors alpha and gamma (ERRα and ERRγ). These nuclear receptors regulate mitochondrial biogenesis, oxidative metabolism, and fatty acid oxidation in skeletal muscle. In published preclinical research, SLU-PP-332 increased exercise capacity, enhanced fatty acid oxidation, and shifted muscle fiber composition toward more fatigue-resistant oxidative fibers — all without actual physical exercise.

The compound gained widespread attention as a potential exercise in a pill candidate. Unlike MOTS-c (which works through AMPK), SLU-PP-332 operates through nuclear receptor activation that directly upregulates the gene expression programs associated with endurance training. Published research in obese mouse models showed that SLU-PP-332 reduced body weight gain and improved metabolic parameters even in sedentary animals.

For researchers, SLU-PP-332 is notable because it is an oral compound (capsule form) rather than a peptide requiring reconstitution and injection. This makes it accessible for a different range of research applications and opens questions about oral bioavailability and tissue distribution that do not apply to injectable peptides.

Key search terms: SLU-PP-332 exercise mimetic, exercise pill research, ERR agonist weight loss, SLU-PP-332 benefits, oral exercise mimetic compound

Tissue Repair and Healing Peptides

The tissue repair category includes some of the most widely studied research peptides, with extensive published literature on wound healing, tendon and ligament repair, gut mucosal integrity, and anti-inflammatory mechanisms.

BPC-157 (Body Protection Compound-157)

BPC-157 is a 15-amino-acid peptide derived from a protective protein found in human gastric juice. It is one of the most extensively studied healing peptides in preclinical research, with published studies spanning tendon repair, muscle healing, bone fracture recovery, gut mucosal protection, nerve regeneration, and vascular repair. The breadth of tissues that BPC-157 appears to affect in preclinical models is unusual — most peptides show specificity for one or two tissue types, while BPC-157 has demonstrated effects across nearly every tissue type tested.

The proposed mechanisms include upregulation of growth factor expression (particularly VEGF, EGF, and their receptors), modulation of the nitric oxide system, interaction with the dopaminergic system, and promotion of angiogenesis (new blood vessel formation). In gut research, BPC-157 has shown protective effects against NSAID-induced gastric damage, alcohol-induced lesions, and inflammatory bowel disease models. In musculoskeletal research, it has accelerated healing of transected tendons, torn muscles, and fractured bones in animal models.

Researchers comparing BPC-157 vs TB-500 note that while both peptides promote tissue repair, they operate through different mechanisms and may affect different phases of the healing cascade, making them subjects of interest for combinatorial research.

Key search terms: BPC-157 peptide research, BPC-157 healing benefits, BPC-157 tendon repair, BPC-157 gut healing, body protection compound research

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic version of the active region of Thymosin Beta-4, a naturally occurring peptide involved in cell migration, blood vessel formation, and tissue repair. Thymosin Beta-4 is found in nearly all human cells and plays fundamental roles in wound healing, particularly in the early inflammatory and proliferative phases.

Published research on TB-500 demonstrates effects on cardiac tissue repair following ischemic injury, dermal wound healing acceleration, hair follicle stem cell migration, corneal repair, and reduction of inflammatory markers. The peptide’s mechanism centers on its interaction with actin, the protein that forms the structural framework of cells — TB-500 sequesters actin monomers, which promotes cell migration and the formation of new blood vessels in damaged tissue.

In the context of tissue repair peptide research, TB-500 is often studied alongside BPC-157 because their mechanisms are complementary. TB-500 primarily promotes cell migration and early-phase healing responses, while BPC-157 appears to act more broadly on growth factor signaling and later-phase tissue remodeling. The “Wolverine blend” — a combination of BPC-157 and TB-500 — has become a common research formulation for investigators studying synergistic healing effects.

Key search terms: TB-500 peptide benefits, thymosin beta-4 research, TB-500 healing peptide, TB-500 vs BPC-157, TB-500 tissue repair

GHK-Cu (Copper Peptide)

GHK-Cu is a naturally occurring tripeptide (Glycyl-L-Histidyl-L-Lysine) with a strong affinity for copper ions. It is found in human plasma, saliva, and urine, with levels that decline significantly with age. GHK-Cu is one of the most studied peptides in skin repair and anti-aging research, with published literature demonstrating effects on collagen synthesis, wound healing, anti-inflammatory signaling, antioxidant enzyme upregulation, and stem cell attraction to injury sites.

What makes GHK-Cu remarkable in research is its gene-modulating activity. Published genomic studies have shown that GHK-Cu affects the expression of over 4,000 genes — roughly 6% of the human genome. It upregulates genes involved in tissue remodeling and repair while downregulating genes associated with inflammation and tissue destruction. This broad gene-regulatory activity has led researchers to investigate GHK-Cu not only for wound healing but also for potential applications in anti-fibrotic research, COPD, and metastasis suppression.

In skin research specifically, GHK-Cu has demonstrated increased collagen and elastin production, improved skin thickness and firmness, accelerated wound closure, and reduced appearance of photodamage in published studies. Researchers studying GHK-Cu vs retinoids note that GHK-Cu promotes collagen synthesis through a different mechanism than retinoids and without the irritation and photosensitivity associated with retinoid use.

Key search terms: GHK-Cu peptide benefits, copper peptide research, GHK-Cu skin repair, GHK-Cu anti-aging peptide, GHK-Cu collagen synthesis

Growth Hormone Secretagogue Peptides

Growth hormone secretagogues (GHS) are compounds that stimulate the body’s own production and release of growth hormone. Unlike direct GH administration, these peptides work through the hypothalamic-pituitary axis, preserving natural feedback loops and pulsatile release patterns. This category includes some of the longest-studied research peptides and remains one of the most active areas of peptide research.

Ipamorelin (Selective GHS Receptor Agonist)

Ipamorelin is a pentapeptide and selective growth hormone secretagogue receptor (GHS-R) agonist. It is considered the most selective of the GHRP (growth hormone releasing peptide) family because it stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels — a selectivity profile that distinguishes it from older GHRPs like GHRP-6 and GHRP-2. This selectivity has made ipamorelin one of the most popular growth hormone peptides for research.

Published research shows that ipamorelin produces dose-dependent increases in growth hormone secretion with a clean hormonal profile. It does not stimulate appetite to the same degree as GHRP-6 (which strongly activates ghrelin pathways), making it suitable for research protocols where confounding hunger effects are undesirable. Researchers studying ipamorelin benefits in preclinical models have reported improvements in bone mineral density, lean body composition, sleep architecture, and recovery from injury.

Ipamorelin is frequently studied in combination with CJC-1295 No DAC (see below) because the two peptides work through complementary mechanisms — ipamorelin triggers GH release pulses while CJC-1295 amplifies the amplitude of those pulses.

Key search terms: ipamorelin peptide research, ipamorelin growth hormone, ipamorelin vs GHRP-6, selective GH secretagogue, ipamorelin benefits and uses

CJC-1295 No DAC (Modified GRF 1-29)

CJC-1295 without DAC — also known as Modified GRF (1-29) or Mod GRF — is a synthetic analogue of the first 29 amino acids of growth hormone releasing hormone (GHRH). The “No DAC” designation means it lacks the Drug Affinity Complex that extends the half-life of the DAC version, giving it a shorter duration of action that more closely mimics natural GHRH pulsatility.

In research, CJC-1295 No DAC amplifies the natural growth hormone release cycle. Rather than creating a constant elevation of GH (as the DAC version does), the No DAC form produces a pulse of GH release that rises and falls over approximately 30 minutes, closely replicating the body’s natural GH secretion pattern. This pulsatile action is considered more physiologically relevant by many researchers because sustained GH elevation can lead to receptor desensitization.

The CJC-1295 and ipamorelin combination has become one of the most commonly researched peptide stacks in the GH secretagogue space. The rationale is mechanistic: CJC-1295 stimulates GH release through the GHRH receptor, while ipamorelin stimulates it through the GHS receptor — two different receptors producing additive or synergistic GH output.

Key search terms: CJC-1295 No DAC peptide, CJC-1295 ipamorelin stack research, modified GRF 1-29, GHRH analogue research peptide, CJC-1295 growth hormone benefits

Longevity and Anti-Aging Peptides

Longevity research has become one of the fastest-growing areas of peptide science, driven by an increasingly detailed understanding of the molecular mechanisms of aging and the discovery of peptides that appear to modulate those mechanisms directly.

Epitalon (Epithalon/Epithalone)

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, which is produced by the pineal gland. It is one of the most studied peptides in telomere research and longevity science. The primary mechanism of interest is epitalon’s ability to activate telomerase — the enzyme responsible for maintaining telomere length at the ends of chromosomes.

Telomere shortening is one of the hallmarks of cellular aging. Each time a cell divides, its telomeres become slightly shorter until they reach a critical length that triggers cellular senescence or apoptosis. Published research on epitalon has demonstrated telomerase activation in human somatic cells, extension of telomere length, and in animal models, significant increases in lifespan. In one notable study, epitalon-treated elderly patients showed improvements in melatonin production, immune function, and markers of physical condition compared to controls.

Beyond telomere effects, epitalon research extends to circadian rhythm regulation (via melatonin normalization), immune function enhancement, antioxidant enzyme activation, and neuroendocrine regulation. Researchers investigating epitalon anti-aging peptide applications consider it one of the few compounds with direct mechanistic evidence for influencing a fundamental aging pathway.

Key search terms: epitalon telomerase activation, epitalon peptide longevity, epithalon anti-aging research, telomere lengthening peptide, epitalon benefits

NAD+ (Nicotinamide Adenine Dinucleotide)

NAD+ is not technically a peptide — it is a coenzyme found in every living cell, essential for energy metabolism, DNA repair, and sirtuin activation. However, it has become a central compound in longevity and metabolic research and is increasingly studied alongside peptides in anti-aging protocols. NAD+ levels decline significantly with age, and this decline is implicated in mitochondrial dysfunction, impaired DNA repair, and metabolic deterioration.

Research on NAD+ supplementation has explored multiple delivery routes. Published studies demonstrate that restoring NAD+ levels activates sirtuins (particularly SIRT1 and SIRT3), enhances mitochondrial function, improves insulin sensitivity, and promotes DNA repair through PARP-1 activation. In preclinical aging models, NAD+ repletion has been associated with improved muscle function, enhanced cognitive performance, and extended healthspan.

The relationship between NAD+ and other longevity pathways makes it a connecting thread in multi-compound research. NAD+ intersects with AMPK activation (relevant to MOTS-c research), sirtuin biology (relevant to caloric restriction mimetics), and mitochondrial function (relevant to SS-31 research). Researchers investigating NAD+ vs NMN vs NR compare direct NAD+ administration with its precursors to determine optimal strategies for cellular NAD+ repletion.

Key search terms: NAD+ research benefits, NAD+ anti-aging, NAD+ sirtuin activation, NAD+ mitochondrial function, NAD+ supplementation research

SS-31 (Elamipretide / Szeto-Schiller Peptide)

SS-31, also known as elamipretide or MTP-131, is a mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane. It interacts directly with cardiolipin, a phospholipid essential for the structural integrity and function of the electron transport chain. By stabilizing cardiolipin and optimizing electron flow through the respiratory complexes, SS-31 enhances ATP production while reducing the generation of reactive oxygen species (ROS) — essentially making mitochondria work more efficiently and produce less damaging waste.

Published research on SS-31 spans heart failure (where it has been studied in human clinical trials as elamipretide), age-related mitochondrial dysfunction, skeletal muscle decline, kidney injury, neurodegenerative disease models, and Barth syndrome (a rare genetic disorder involving cardiolipin metabolism). The peptide’s unique ability to target mitochondria directly — rather than relying on cell-surface receptor signaling — gives it access to a fundamental mechanism of cellular energy production and aging.

Researchers comparing SS-31 vs CoQ10 or other mitochondrial supplements note that SS-31 targets a different component of the mitochondrial machinery (cardiolipin rather than Complex I/II) and achieves mitochondrial concentrations that oral supplements cannot reach.

Key search terms: SS-31 peptide research, elamipretide benefits, mitochondria targeted peptide, SS-31 anti-aging, SS-31 cardiolipin research

Cognitive and Neuroprotective Peptides

Neuroprotective peptides represent a growing research area driven by interest in cognitive enhancement, neurodegenerative disease prevention, and brain injury recovery. These compounds act through various mechanisms including neurotrophic factor modulation, neurotransmitter system regulation, and neuroinflammation reduction.

N-Acetyl Semax (Modified ACTH Fragment)

N-Acetyl Semax is an enhanced version of Semax, which itself is a synthetic analogue of the ACTH (adrenocorticotropic hormone) fragment 4-10. The N-acetyl modification improves stability and bioavailability compared to native Semax. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax and its derivatives have been extensively studied for cognitive enhancement and neuroprotection.

Published research on Semax and N-Acetyl Semax demonstrates upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), enhancement of attention and memory in both healthy and cognitively impaired models, neuroprotective effects against ischemic brain injury, and modulation of serotonergic and dopaminergic neurotransmission. The compound is administered as a nasal spray, providing direct access to the central nervous system through the nasal mucosa.

Researchers investigating nootropic peptides consider N-Acetyl Semax one of the most well-documented peptide-based cognitive enhancers in published literature. Its effects on BDNF — the primary neurotrophin involved in synaptic plasticity and memory formation — are of particular interest to researchers studying learning, neuroplasticity, and recovery from neurological insult.

Key search terms: N-Acetyl Semax nootropic, Semax peptide cognitive benefits, Semax BDNF research, neuroprotective peptide research, Semax nasal spray research

Sexual Health and Hormonal Peptides

Peptides that modulate sexual function and hormonal signaling represent a distinct research category with mechanisms that differ fundamentally from traditional hormone replacement. These compounds act through central nervous system pathways rather than directly supplying exogenous hormones, making them of particular interest for researchers studying the neurobiology of sexual function.

PT-141 (Bremelanotide)

PT-141, also known as bremelanotide, is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin-4 receptors (MC4R) in the central nervous system. Unlike PDE5 inhibitors (such as sildenafil), which work through peripheral vascular mechanisms, PT-141 acts directly on brain pathways that regulate sexual arousal and desire. This central mechanism makes it the only compound in its class that addresses sexual desire at the neurological level rather than simply facilitating the vascular mechanics of sexual response.

Published clinical research on PT-141 demonstrated statistically significant improvements in sexual desire, arousal, and satisfaction in both male and female subjects. It received FDA approval as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first melanocortin-based therapy approved for sexual dysfunction. In research settings, PT-141 is studied for its effects on both male and female sexual function, its interaction with the melanocortin system, and its potential applications beyond sexual health (the melanocortin system also influences appetite, inflammation, and energy homeostasis).

Researchers comparing PT-141 vs traditional approaches note that PT-141’s mechanism of action — central MC4R activation — represents a fundamentally different pharmacological strategy that may be effective in cases where peripheral vasodilators are insufficient, particularly in cases involving desire rather than arousal dysfunction.

Key search terms: PT-141 peptide research, bremelanotide mechanism of action, PT-141 sexual health peptide, melanocortin receptor agonist research, PT-141 benefits for research

Kisspeptin-10 (Metastin 45-54)

Kisspeptin-10 is a truncated, biologically active fragment of the kisspeptin family of peptides that plays a master regulatory role in the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin neurons in the hypothalamus are the primary upstream trigger for GnRH (gonadotropin-releasing hormone) secretion, which in turn drives LH and FSH release — the hormones that control testosterone production in males and ovarian function in females.

Published research on kisspeptin has demonstrated potent stimulation of LH and FSH secretion, with downstream increases in testosterone and estradiol. Beyond reproductive endocrinology, kisspeptin research has expanded into areas including pubertal development, metabolic-reproductive axis interactions, and the neurobiology of sexual arousal. Recent published studies have shown that kisspeptin administration enhances sexual and emotional brain processing in healthy volunteers, suggesting effects beyond simple gonadotropin stimulation.

For researchers studying natural testosterone optimization or hypothalamic-pituitary regulation, kisspeptin-10 provides a tool to stimulate the reproductive axis at its most upstream physiological trigger point — above GnRH itself. This is distinct from direct GnRH administration, hCG stimulation, or exogenous testosterone, each of which enters the cascade at a different point.

Key search terms: kisspeptin-10 peptide research, kisspeptin testosterone, kisspeptin GnRH stimulation, kisspeptin reproductive research, kisspeptin-10 benefits

Oxytocin (The Bonding Peptide)

Oxytocin is a nine-amino-acid neuropeptide produced in the hypothalamus and released by the posterior pituitary. Often called the “bonding hormone” or “love hormone,” oxytocin plays well-documented roles in social bonding, trust, empathy, maternal behavior, pair bonding, and stress regulation. It is one of the most studied neuropeptides in all of neuroscience.

Research applications for oxytocin extend well beyond its popular reputation. Published studies have investigated oxytocin’s effects on autism spectrum disorder (where it has shown improvements in social cognition and eye contact), anxiety and PTSD (where it modulates amygdala reactivity), wound healing (oxytocin receptors are present in skin and promote tissue repair), pain modulation, and metabolic regulation. The peptide’s role in gut function is also emerging — oxytocin receptors are present throughout the GI tract, and research suggests it may influence gut motility and inflammation.

For researchers, oxytocin is available as a nasal spray formulation, providing direct access to the CNS. Intranasal delivery bypasses the blood-brain barrier limitations that restrict many peripherally administered peptides from reaching central targets.

Key search terms: oxytocin research peptide, oxytocin social behavior research, oxytocin anxiety research, oxytocin nasal spray research, oxytocin benefits studies

How to Choose the Right Research Peptide: A Category Comparison

With so many compounds available, researchers new to the peptide space often ask which compounds are most relevant to their area of investigation. The following framework organizes every peptide covered in this guide by primary research application, helping researchers quickly identify which compounds align with their protocols.

For Metabolic and Weight Loss Research

The most active area of peptide research in 2026. Researchers have a spectrum of options from single-target to multi-target compounds. Retatrutide (triple agonist) offers the broadest incretin-based mechanism. Tirzepatide (dual agonist) provides the most clinical data to reference. Tesamorelin targets visceral fat specifically through GH pathways. MOTS-c operates through an entirely different mechanism (AMPK/mitochondrial) and complements incretin research. SLU-PP-332 targets exercise-related metabolic pathways through nuclear receptor activation. Each addresses a different facet of metabolic dysfunction, and multi-compound research protocols are increasingly common.

For Tissue Repair and Recovery Research

BPC-157 has the broadest evidence base across tissue types. TB-500 excels in early-phase healing and cell migration research. GHK-Cu is strongest for skin repair, collagen synthesis, and gene-regulatory research. The Wolverine blend (BPC-157 + TB-500) is a popular combination for synergistic healing research. Researchers should note that these compounds act through fundamentally different mechanisms, making them complementary rather than redundant.

For Longevity and Anti-Aging Research

Epitalon targets telomere biology directly. NAD+ addresses cellular energy metabolism and sirtuin-mediated repair pathways. SS-31 optimizes mitochondrial electron transport and reduces oxidative damage. GHK-Cu modulates thousands of aging-related genes. MOTS-c bridges metabolic and longevity research through its exercise-mimetic effects. This category benefits from multi-compound approaches because aging involves multiple simultaneous mechanisms — no single compound addresses all of them.

For Cognitive and Neuroprotective Research

N-Acetyl Semax is the most directly studied nootropic peptide, with strong BDNF and NGF upregulation data. Oxytocin modulates social cognition and amygdala-mediated emotional processing. SS-31 addresses the mitochondrial component of neurodegeneration. BPC-157 has emerging neuroprotective data including effects on dopaminergic pathways. Cognitive research increasingly recognizes that neurodegeneration involves both neurochemical and bioenergetic components, making combination approaches relevant.

For Growth Hormone and Body Composition Research

The classic GH secretagogue stack — CJC-1295 No DAC + Ipamorelin — remains the most widely researched combination for stimulating natural GH release. Tesamorelin provides an alternative GHRH-based approach with stronger clinical data on visceral fat reduction. Each works through the hypothalamic-pituitary axis rather than providing exogenous GH, preserving natural feedback mechanisms.

For Sexual Health and Reproductive Research

PT-141 targets central nervous system sexual arousal pathways through melanocortin receptors. Kisspeptin-10 stimulates the reproductive axis at the most upstream physiological trigger point. Oxytocin modulates bonding, trust, and the social components of sexual and romantic relationships. These three compounds act through entirely different mechanisms, each addressing a distinct aspect of sexual health biology.

Research Peptide Safety Considerations

All research peptides require careful handling, proper storage, and appropriate reconstitution. General considerations for researchers include proper cold-chain storage (most peptides require refrigeration after reconstitution), use of bacteriostatic water for reconstitution, sterile technique for preparation, and awareness that peptide stability varies significantly between compounds. Researchers should consult published literature for compound-specific stability data and storage requirements.

It is also critical for researchers to source peptides from suppliers that provide third-party testing documentation, including HPLC purity analysis and mass spectrometry verification. Peptide purity directly affects research reproducibility — impurities can confound results and lead to incorrect conclusions about a compound’s biological activity.

Browse our full catalog of research-grade peptides, each with published third-party purity testing, at praxpeptides.com/shop.

The Future of Peptide Research: What Is Coming Next

The peptide research landscape continues to expand in several directions simultaneously. Multi-receptor agonism is producing compounds of increasing complexity — from dual agonists to triple agonists to the recently published quintuple agonist (GLP-1/GIP/PPARα/γ/δ). Targeted delivery strategies like peptide-drug conjugation are opening new possibilities for delivering small-molecule drugs at dramatically reduced doses. Mitochondrial-targeted peptides are revealing new approaches to aging and metabolic disease that bypass traditional receptor-based pharmacology.

Oral delivery platforms for traditionally injectable peptides are advancing rapidly, potentially transforming the accessibility of peptide research. And the discovery of new endogenous peptides — like the mitochondrial-derived peptides (MOTS-c, humanin, SHLP peptides) — continues to reveal signaling systems that were previously unknown, opening entirely new research frontiers.

For researchers in 2026, the message is clear: the peptide field is broader, more mechanistically diverse, and more promising than at any point in its history. Understanding the full landscape — from incretin agonists to mitochondrial peptides, from healing compounds to cognitive enhancers — is essential for designing informed, effective research protocols.

Explore our complete selection of research-grade peptides at praxpeptides.com/shop.

All compounds discussed in this article are intended strictly for in-vitro research and laboratory use only. They are not intended for human consumption, veterinary use, or any clinical application. Researchers are responsible for ensuring compliance with all applicable regulations in their jurisdiction.